| Han, Yaling |
NCT03287167: Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease |
|
|
| Recruiting | 4 | 1720 | RoW | 1 month DAPT, 6 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy | 07/21 | 07/23 | | |
| Active, not recruiting | 3 | 428 | RoW | MiStent, TIVOLI | Micell Technologies, Hefei Life Science Medical Instruments Co. Ltd., Giant Med-Pharma Services Inc., CCRF Consulting Co., Ltd. | Coronary Heart Disease | 11/18 | 11/22 | | |
VCP1-III-01, NCT06577519: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) |
|
|
| Recruiting | 3 | 1000 | RoW | Vicagrel, Clopidogrel | Jiangsu vcare pharmaceutical technology co., LTD | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 12/26 | 12/26 | | |
PADN-HF-PH, NCT05824923: A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure |
|
|
| Recruiting | 3 | 264 | RoW | Pulmonary arterial denervation, PADN, Guideline-directed medical therapy (GDMT) for heart failure, GDMT medication for heart failure | Pulnovo Medical (Wuxi) Co., Ltd., The General Hospital of Northern Theater Command, The First Affiliated Hospital with Nanjing Medical University, First Hospital of Tsinghua University, Cangzhou Central Hospital, Fuwai Central China Cardiovascular Hospital, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Shanxi Cardiovascular Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Beijing Anzhen Hospital, West China Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, TEDA International Cardiovascular Hospital, Tianjin Medical University General Hospital, Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, First Affiliated Hospital Xi'an Jiaotong University, Xiamen Cardiovascular Hospital, Xiamen University, Zhejiang University, Shengjing Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Gansu Provincial Hospital, Yanan Hospital of Kunming City, First Affiliated Hospital of Chongqing Medical University, Huaihe Hospital of Henan University, Zhengzhou Cardiovascular Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, Hunan Provincial People's Hospital, Tianjin Medical University Second Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Hospital of Jilin University | Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction | 08/25 | 02/27 | | |
NCT03040934: Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s) |
|
|
| Active, not recruiting | N/A | 196 | RoW | Firehawk sirolimus target eluting coronary stent system, Firehawk™, XIENCE Everolimus-Eluting Coronary Stent System, XIENCE EES | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention, Tomography, Optical Coherence | 09/19 | 10/23 | | |
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 325 | RoW | FFR and FFRCT | CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China | Coronary Stenosis | 10/21 | 03/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT05988450: Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation |
|
|
| Active, not recruiting | N/A | 125 | RoW | SQ-Kyrin Transcatheter Mitral Valve Repair System | Shanghai Shenqi Medical Technology Co., Ltd | Functional Mitral Regurgitation | 12/23 | 12/27 | | |
NCT06357026: Phitys I™ Percutaneous Left Ventricular Assist System Study |
|
|
| Not yet recruiting | N/A | 344 | RoW | Percutaneous Ventricular Assist System（Phigine Medical）, intra-aortic balloon pump (IABP) | Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd. | Coronary Artery Disease | 05/25 | 04/26 | | |
NCT05864456: Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study |
|
|
| Recruiting | N/A | 73 | RoW | Prizvalve Pro™ transcatheter aortic valve system | Shanghai NewMed Medical Co., Ltd., The General Hospital of Northern Theater Command, West China Hospital | Aortic Valve Stenosis | 06/24 | 05/28 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
| Not yet recruiting | N/A | 10 | RoW | DragonFire Transcatheter Myocardial Radiofrequency Ablation System | Hangzhou Valgen Medtech Co., Ltd | Obstructive Hypertrophic Cardiomyopathy | 06/25 | 06/26 | | |
NCT06639321: Phimume® Percutaneous Left Ventricular Assist System Study |
|
|
| Not yet recruiting | N/A | 250 | RoW | Percutaneous Ventricular Assist System, extracorporeal membrane oxygenation (ECMO) | Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd. | Coronary Artery Disease | 11/25 | 10/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
CRUISE-CTO, NCT04944615: To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease. |
|
|
| Recruiting | N/A | 1448 | RoW | The guidewire successfully passed the CTO lesion, Load dose administration | CCRF Inc., Beijing, China, BSC International Medical Trading (Shanghai) Co., Ltd. | Chronic Total Occlusion of Coronary Artery | 10/31 | 10/31 | | |
| Li, Yan |
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
NCT05299697: A Study of TG103 Injection in Overweight or Obesity |
|
|
| Recruiting | 2 | 195 | RoW | TG103 15 mg, TG103 22.5 mg, Placebo | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Overweight or Obesity | 06/23 | 09/23 | | |
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV |
|
|
| Recruiting | 2 | 60 | RoW | Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo | Vigonvita Life Sciences | Respiratory Syncytial Virus Infection | 01/25 | 01/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627 | Novartis Pharmaceuticals | IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy | 07/24 | 07/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
| Recruiting | 1 | 76 | RoW | HS-10380, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia | 06/23 | 07/23 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Fan, Jia |
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) |
|
|
| Not yet recruiting | 4 | 600 | NA | Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Unresectable Hepatocellular Carcinoma | 09/25 | 01/27 | | |
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 490 | RoW | IBI310, Sintilimab, Sorafenib | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 425 | RoW | TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 07/26 | 07/26 | | |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. |
|
|
| Recruiting | 2 | 117 | RoW | HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 02/27 | 02/27 | | |
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 55 | RoW | Anlotinib and TQB2450 | Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 10/25 | 12/25 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 06/28 | 06/28 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT06584071: A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC |
|
|
| Not yet recruiting | 1/2 | 140 | NA | PM8002, PM1009, atezolizumab, bevacizumab | Biotheus Inc. | HCC, Liver Cancer | 10/26 | 12/27 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
| Shen, Lin |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 3 | 194 | RoW | Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI | Hutchison Medipharma Limited | Advanced Neuroendocrine Carcinoma | 05/25 | 05/25 | | |
FG-M108-04, NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. |
|
|
| Recruiting | 3 | 486 | RoW | M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 01/27 | 04/27 | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
NCT06304974: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 488 | RoW | BL-B01D1, Irinotecan, paclitaxel, docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | 05/26 | 05/26 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 506 | RoW | cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo | Akeso | Gastric and Gastroesophageal Junction Adenocarcinoma | 11/26 | 07/27 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
HLX22-GC-301, NCT06532006: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer |
|
|
| Recruiting | 3 | 550 | Japan, RoW | HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech, Henlius USA | Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer | 06/27 | 09/28 | | |
NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety |
|
|
| Recruiting | 3 | 590 | RoW | QL1203, Placebo, mFOLFOX6 regimen | Qilu Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 12/24 | 07/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 04/26 | 07/29 | | |
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets | RemeGen Co., Ltd. | Gastric Cancer | 07/24 | 07/25 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT04705519: Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 100 | RoW | Nab-paclitaxel Combined With Bevacizumab | Peking University, Qilu Pharmaceutical Co., Ltd. | Neuroendocrine Carcinoma | 01/22 | 01/24 | | |
SEARCH-01, NCT04521179: Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors |
|
|
| Completed | 2 | 102 | RoW | KN026 combination, IO therapy | Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University | HER2-positive Solid Tumors | 01/22 | 05/23 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. |
|
|
| Recruiting | 2 | 40 | RoW | SI-B001, Irinotecan | Sichuan Baili Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinomas | 06/25 | 06/25 | | |
| Recruiting | 2 | 200 | RoW | KN035 | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 12/24 | 12/25 | | |
NCT06222944: Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA |
|
|
| Not yet recruiting | 2 | 90 | RoW | Anlotinib, Anlotinib Hydrochloride Capsule, TQB2450, Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound) | Peking University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 08/25 | 08/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT04891198: ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 126 | RoW | Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 08/27 | 04/28 | | |
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 47 | RoW | Utidelone and anlotinib | Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Esophageal Cancer | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 360 | RoW | QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 06/26 | 12/27 | | |
NCT05628857: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor |
|
|
| Recruiting | 2 | 240 | RoW | RC108 | RemeGen Co., Ltd. | Digestive Cancer | 10/24 | 10/25 | | |
NCT04923932: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients |
|
|
| Recruiting | 2 | 75 | RoW | Savolitinib, hmpl-504 | Hutchison Medipharma Limited | Gastric Cancer, Esophagogastric Junction Disorder | 04/25 | 10/25 | | |
|
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT06008054: A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors |
|
|
| Recruiting | 2 | 376 | RoW | SI-B003, BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Colorectal Cancer | 12/25 | 12/25 | | |
| Recruiting | 2 | 300 | RoW | Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132 | Gilead Sciences | Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | 2 | 200 | RoW | Tislelizumab (BGB-A317) | BeiGene | MSI-H/dMMR Solid Tumors | 11/26 | 09/27 | | |
|
| Completed | 1/2 | 65 | RoW | CS3007 (BLU-285) | CStone Pharmaceuticals, Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors | 04/20 | 04/23 | | |
|
|
NCT03565003: A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China |
|
|
| Completed | 1/2 | 126 | RoW | JAB-3068 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors | 01/23 | 01/23 | | |
AK109-201, NCT04982276: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 138 | RoW | AK109, paclitaxel, AK104 | Akeso | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 10/25 | 01/27 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06157827: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 1/2 | 178 | RoW | LBL-024 for Injection, LBL-024, Etoposide Injection, Etoposide, Carboplatin Injection, Carboplatin, Atezolizumab injection, Atezolizumab, Cisplatin injection, Cisplatin | Nanjing Leads Biolabs Co.,Ltd | Advanced Neuroendocrine Carcinoma | 11/26 | 07/27 | | |
